Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002) Average of 28% NfL reduction observed in an NfL responder subset (geometric mean ratio, change at Week 76 post-baseline: 0.72, p<0.0001) More than 650 patient years of CNM-Au8 treatment exposure without any identified safety signals SALT LAKE CITY, June 18, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiari ...

Clene Inc. (CLNN) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.06, delivering a surprise of 14.29%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Clene, which belongs to the Zacks Medical ...

Exhibit 99.1 CLENE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) ● Peer-reviewed publication characterized the protein corona of CNM-Au8 ● Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access Program ● Cash, cash equivalents and ...

Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) Peer-reviewed publication characterized the protein corona of CNM-Au8 Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access Program Cash, cash equivalents and marketable securities of $27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 01-39834 CLENE INC. (Exact name of registrant as specified in its charter) Delaware 85-2828339 (State o ...

LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ:CLNN), recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg S ...

Clene Inc.和Clene Nanomedicine, Inc.在AAN年会上展示Phase 2 VISIONARY-MS LTE研究结果 - CNM-Au8治疗在患有多发性硬化症（MS）的患者中显示出修复和重髓鞘效应的证据[3] - CNM-Au8治疗导致了多个临床和临床外端点的显著改善，包括认知和视觉功能[5] - CNM-Au8治疗对神经元功能和重髓鞘的生理和结构证据显示出显著改善[8][9] - CNM-Au8治疗在三年的辅助治疗中持续改善多个临床和临床外端点，为进行第三阶段研究提供了明确的动力[11]

Clene公司介绍 - Clene Inc.（NASDAQ:CLNN）是一家临床阶段的生物制药公司，总裁、董事长和首席执行官Rob Etherington最近在First in Human播客上接受了采访[1] Clene公司的药物研究 - Clene公司在纳米技术领域的工作受到了关注，他们的药物CNM-Au8®在两项肌萎缩侧索硬化症（ALS）研究和一项多发性硬化症研究中表现出改善功能的能力[2] Clene公司的技术优势 - Clene公司的纳米技术方法使其在治疗选择方面与传统方法有所区别，该公司的管线项目得到了详细讨论[3]

Proprietary catalytic gold nanocrystals comprising Clene's investigational drug CNM-Au8® develop a protein corona upon exposure to human blood plasma comprised of proteins that promote blood-brain barrier penetration, an important feature of the drug's neuroprotective mechanism of action The protein corona attracted by CNM-Au8 nanocrystals prevents aggregation upon entering the bloodstream, enabling the drug's longevity in circulation without provoking an inflammatory response SALT LAKE CITY, March 15, 2024 ...

Clene Inc.财务表现 - Clene Inc.在上个季度每股亏损为$0.06，好于Zacks Consensus Estimate的每股亏损$0.07，较去年同期每股亏损$0.16有所改善[1] - Clene Inc.这一季度的盈利出乎意料，盈利惊喜达到了14.29%。在过去的四个季度中，公司四次超过了市场预期的每股收益[2] - Clene Inc.在2023年12月份的季度营收为$0.17百万，超过了Zacks Consensus Estimate 21.43%。公司在过去四个季度中两次超过了市场预期的营收[3] Clene Inc.股价表现 - Clene Inc.股价的持续增长主要取决于管理层在财报电话会议中的评论。自年初以来，Clene Inc.的股价上涨了约49.7%[4] Clene Inc.行业地位 - Clene Inc.在医疗-生物医学和遗传学行业，投资者关注公司未来的盈利前景，以及近期的盈利预期变化[5] - 投资者可以通过追踪盈利预期修订来了解股票的短期走势，Clene Inc.的盈利预期修订趋势不一，目前的Zacks Rank为3 (Hold)[6] 行业比较 - 投资者应该注意行业前景对股票表现的影响，医疗-生物医学和遗传学行业目前在Zacks行业排名中处于前31%[7] Allogene Therapeutics财务预期 - 同行业的另一家公司Allogene Therapeutics (ALLO)尚未公布2023年12月季度的财报，预计将于3月14日发布[8] - Allogene Therapeutics预计在即将发布的财报中每股亏损$0.47，同比增长28.8%，营收预计为$0.05百万，较去年同期下降8%[9]